Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story.

Abstract

Cytomegalovirus retinitis (CMVR) following hematopoietic stem cell transplantation (HCT) for a primary immunodeficiency is a rare but highly morbid condition with potential irreversible consequences despite optimal antiviral pharmacotherapy. Viral-specific T cells (VSTs) pose a promising and safe approach eradicating intractable viral disease. We describe the case of a 21-month-old male with Wiskott-Aldrich syndrome (WAS) and CMVR post HCT with sustained long-term virologic and clinical response after CMV-specific T-cell therapy. This case highlights the need to consider VST as an adjunct upfront strategy in refractory CMVR and for routine ophthalmologic screening and surveillance in high-risk patients post HCT.

• Authors: Raul Montiel-Esparza, Suzanne M Michalak, Anthony Huy Dinh Le, Christopher Or, Quan Dong Nguyen, Ruby Khoury, Michael S Grimley, Alice Bertaina, Edna Klinger, Ami J Shah, Edward H Wood
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 70 Issue 8 Pg. e30429 (Aug 2023) ISSN: 1545-5017 [Electronic] United States
• PMID: 37243390 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2023 Wiley Periodicals LLC.

Chemical References

• Antiviral Agents
• Phosphoproteins

Topics

• Humans
• Male
• Infant
• Cytomegalovirus Retinitis (therapy, drug therapy)
• Antiviral Agents (therapeutic use)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Phosphoproteins
• T-Lymphocytes